Oprah Winfrey leaves the WeightWatchers board

Oprah Winfrey told WW International that she would not stand for re-election to its board at the company's May 2024 annual shareholder meeting, ending a nearly decade-long run as a director ^[1]. The news, disclosed on Feb. 29, 2024, sent WeightWatchers shares down 25% in premarket trading ^[1]. Winfrey also said she is donating all of her WW stock to the National Museum of African American History and Culture ^[1].

At the time of the announcement, no reason was given. A WeightWatchers regulatory statement said her "decision was not the result of any disagreement" or "any matter relating to the company's operations, policies or practices" ^[1]. Two weeks later, on "Jimmy Kimmel Live!", Winfrey explained it herself: she was preparing a prime-time ABC special on weight-loss drugs and wanted to "be able to talk about whatever I want to talk about" ^[2]. WeightWatchers, she said, "is now in the business of being a weight-health company that also administers drug medications for weight. I did not want to have the appearance of any conflict of interest" ^[2].

The numbers behind the exit

Winfrey joined the board in 2015 and bought a 10% stake, which gave the company a jolt of relevance as dieters drifted away from point-counting programs ^[1]. Her original purchase was 6.4 million shares for $43.2 million ^[2]. By March 2024 she held about 1.1 million shares, a 1.43% stake worth roughly $2.5 million, according to FactSet data cited by Variety ^[2]. Her departure came a year earlier than planned; in 2019 she had signed an extension running through 2025 ^[1].

The stock damage was not new. ABC7/CNN reported that if the Feb. 29 premarket losses held, WW shares would be down 85% over the prior six months ^[1]. The company has been squeezed as GLP-1 prescription drugs such as Ozempic and Wegovy — both semaglutide — have taken hold ^[1]. WeightWatchers responded by launching a membership plan for people on those medications that includes access to doctors who can prescribe them, daily nutrition plans, insurance coordination and other support ^[1]. It also bought Sequence, a telehealth service that connects patients with clinicians who can prescribe weight-loss drugs. The sources give slightly different prices: ABC7/CNN describes it as a "$100 million-plus deal" ^[1], while Variety puts the figure at $106 million ^[2].

WW's board said it supported the donation, which was set for the company's March 2024 trading window, adding that Winfrey was making it "to eliminate any perceived conflict of interest around her taking weight-loss medications," and that she intends to donate proceeds from any future stock option exercises to the museum as well ^[2]. On Kimmel, Winfrey put it more bluntly: she gave the shares away "so nobody can say, 'Oh, she's doing that special, she's making money'" ^[2][3].

Why it matters for patients

Winfrey is not a doctor, and nothing here changes what any GLP-1 medication does. But the episode is a useful window into how commercial interests sit alongside health messaging in this category. A public figure who had spent years as a paid director and shareholder at a weight-loss company concluded that the connection could color how her drug coverage was received — and cut the financial tie before going on air ^[2][3].

It also shows how quickly the business of weight management is reorganizing around prescription drugs. A company built on group meetings and food points now sells telehealth access to prescribers ^[1][2]. For patients, that means the same brand may be offering both behavioral programs and a path to a prescription, which is worth keeping in mind when weighing where health advice is coming from.

Winfrey disclosed in December 2023 that she had added a weight-loss medication to her routine, but she has not said which one ^[1][3]. "I now use it as I feel I need it, as a tool to manage not yo-yoing," she told People ^[3].

What happens next

• March 2024: Winfrey's shares were slated to be donated during WW's March trading window ^[2].
• Monday, March 18, 2024: "An Oprah Special: Shame, Blame and the Weight Loss Revolution" airs on ABC, streaming the next day on Hulu, with medical experts and patients discussing drugs including Ozempic, Mounjaro and Wegovy ^[2][3]. ABC said the special will cover who the drugs are intended for and their short- and long-term side effects ^[3].
• May 2024: WW's annual shareholder meeting, where Winfrey's term ends ^[1].

What the special will actually conclude about risks, costs or coverage is not known from these sources.